Gilead Sciences



Ebitda változás Dátum
AbbVie USD 6.92B 258M 2024-12
Agios Pharmaceuticals USD -123670000 22.2M 2024-12
ALKERMES USD 163.42M 40.22M 2024-12
Alnylam Pharmaceuticals USD -90991000 28.07M 2024-12
Amgen USD 3.71B 265M 2024-12
Biogen USD 754.8M 7.2M 2024-12
BioMarin Pharmaceutical USD 194.85M 18.43M 2024-12
Bristol-Myers Squibb USD 4.91B 445M 2024-12
Eli Lilly USD 6.17B 1.27B 2024-12
Gilead Sciences USD 3.21B 651M 2024-12
GlaxoSmithKline GBP 2.08B 1.22B 2024-12
Glaxosmithkline GBP 1.69B 1.6B 2024-12
Incyte USD 320.2M 128.19M 2024-12
J&J USD 6.12B 1.51B 2024-12
Merck USD 7.12B 1.06B 2024-12
Moderna USD -993000000 1.19B 2024-12
Neurocrine Biosciences USD 152.1M 39.2M 2024-12
Novartis USD 5.19B 319M 2024-12
Pfizer USD 4.71B 3.04B 2024-12
PTC Therapeutics USD 1.07M 47.25M 2024-12
Regeneron Pharmaceuticals USD 1.06B 572.8M 2024-12
Sanofi EUR 4.25B 2.22B 2024-09
Sarepta Therapeutics USD 182.21M 150.21M 2024-12
United Therapeutics USD 383.4M 43.9M 2024-12
Vertex Pharmaceuticals USD 1.16B 24.5M 2024-12



Gilead Sciences - Az oldal aktuális és múlbeli adatokat, elorejelzéseket, statisztikákat, grafikonokat és a gazdasági naptár adatait tartalmazza - Mar 2025.